ライフサイエンスコーパス: cancer of the prostate

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 bs, is used as a nonestrogenic treatment for cancer of the prostate.

2 ) has been widely used as a serum marker for cancer of the prostate.

3 1 mutation carriers are at increased risk of cancers of the prostate and breast.

4 Such lesions have been noted in cancers of the prostate and endometrium and in glioblast

5 61 cell lines/xenografts derived from human cancers of the prostate, breast, ovary, endometrium, cer

6 nd its soluble receptor (uPAR) would predict cancer of the prostate (CaP) presence, stage, and progno

7 Second only to skin cancer, cancer of the prostate gland (CaP) is the most commonly

8 and disorders were inflammatory diseases and cancer of the prostate gland in Vav3 transgenic mice.

9 Cancer of the prostate gland is one of the most common m

10 Cancer of the prostate gland is the highest unavoidable

11 ols from a population-based study in Sweden [CAncer of the Prostate in Sweden (CAPS)] using Affymetri

12 pulation-based case-control study in Sweden [Cancer of the Prostate in Sweden (CAPS)].

13 study populations: the remaining subjects in Cancer of the Prostate in Sweden and a hospital-based ca

14 Swedish population-based case-control study (CAncer of the Prostate in Sweden), including 2899 cases

15 3.67, 95% CI 1.39-9.68), but there were also cancers of the prostate (IRR 3.46, 95% CI 1.25-9.59), la

16 prostatectomy in the management of localized cancer of the prostate is one such example.

17 ted by somatic CpGisland hypermethylation in cancers of the prostate, liver, and breast.

18 y 31, 2001, for the primary diagnosis of new cancer of the prostate, lung (nonsmall cell), breast, di

19 srectal US was performed in 12 subjects with cancer of the prostate prior to radical prostatectomy.

20 surgery have been in the domain of localized cancer of the prostate (radical prostatectomy), bladder

21 d over NCCN (0.73; 95% CI, 0.60 to 0.86) and Cancer of the Prostate Risk Assessment (0.74; 95% CI, 0.

22 sessed using the D'Amico risk groups and the Cancer of the Prostate Risk Assessment (CAPRA) score.

23 ients were identified by using the validated Cancer of the Prostate Risk Assessment (CAPRA) score.

24 A novel instrument (Japan Cancer of the Prostate Risk Assessment [J-CAPRA]) was de

25 nd a standard postoperative risk assessment (Cancer of the Prostate Risk Assessment post-Surgical [CA

26 l margins (9.8% v 5.9%; P = .02), and higher Cancer of the Prostate Risk Assessment Post-Surgical sco

27 edical centers were matched according to the Cancer of the Prostate Risk Assessment postsurgical scor

28 740 men in the United States community-based Cancer of the Prostate Strategic Urologic Research Endea

29 Data were abstracted from the Cancer of the Prostate Strategic Urologic Research Endea

30 A community-based cohort (community-based Cancer of the Prostate Strategic Urologic Research Endea

31 of 2004-2005, who were participating in the Cancer of the Prostate Strategic Urologic Research Endea

32 METHODS By utilizing data abstracted from Cancer of the Prostate Strategic Urologic Research Endea

33 clinical sites that contributed data to the Cancer of the Prostate Strategic Urologic Research Endea

34 ancer, including 12 patients with small cell cancer of the prostate, underwent CT before platinum-bas

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。